Ascrinvacumab

DB12261InvestigationalProtein Based Therapies

Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.

Mechanism: Pharmacologically active on Activin receptor type-1-like
Curator reviewed
Code names: GT90001 · PF-03446962

Resolves to

Compound

UNII716FQ5REVOCAS1463459-96-2

Targets

P37023ACVRL1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ascrinvacumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account